<DOC>
	<DOC>NCT02102646</DOC>
	<brief_summary>The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.</brief_summary>
	<brief_title>MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism</brief_title>
	<detailed_description>This is a substudy of the ongoing randomized trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin (EudraCT number: 2013-002553-29). 20 consecutive patients are anticipated to participate regardless of assignment to either orchiectomy or triptorelin.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Eligible for inclusion are patients who are included in the already ongoing Randomised trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin (EudraCT number: 201300255329) Implanted devices or foreign metallic bodies incompatible with Magnetic Resonance Imaging. claustrophobia Severe Psychiatric disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>